Oral amoxicillin (50 mg/kg/day) thrice daily is the first-line therapy for non-severe childhood pneumonia. Compliance could be enhanced if two daily doses are employed. We assessed the equivalence of oral amoxicillin (50 mg/kg/day) thrice or twice daily in those patients.
Introduction
Pneumonia is one of the leading infectious diseases in childhood; in 2010, in children ,5 years old, there were 120 million episodes globally, of which 88% were non-severe. 1 Different international guidelines recommend amoxicillin as first-line therapy for those non-severe cases, 2 which is based on the assumption that Streptococcus pneumoniae is the most common bacterial pathogen. 3 The US guidelines recommend amoxicillin at 90 mg/kg/day in two doses or 45 mg/kg/day in three doses in regions where the upper MIC for S. pneumoniae is ≤2.0 mg/L. 4 In 2013, the WHO launched a recommendation for the management of childhood illnesses in which outpatients with pneumonia in low HIV prevalence regions should receive amoxicillin at 40 mg/kg per dose twice a day. 5 As per the initial paediatric registration trials for amoxicillin in the early 1970s, the standard dosage therapy (15 mg/kg/dose thrice daily) appeared to be uniformly successful and so it was approved. 6 However, higher compliance is expected if the drug is administered twice a day. 7 To date, no clinical trial has assessed the equivalence of oral amoxicillin given thrice or twice daily at 50 mg/kg/day to children with non-severe pneumonia and we aimed to achieve this goal.
Patients and methods

Study design and patient selection
We conducted a randomized, controlled, triple-blinded equivalence trial of amoxicillin (50 mg/kg/day) given orally thrice or twice daily to children aged 2 -59 months with non-severe pneumonia, in the emergency room of the university hospital in Salvador, Brazil. Participants were randomized (1: 1) into two groups. Potentially eligible cases were identified by paediatricians based on the report of respiratory complaints and the detection of lower respiratory findings plus presence of pulmonary infiltrate/consolidation on the chest radiograph (CXR) (frontal and lateral views) taken on admission. At this moment, the CXR was read by the paediatricians. The exclusion criteria are presented in Table 1 .
Before enrolment, a written informed consent was obtained from the parents/legal guardians when those caregivers agreed to stay in the hospital with the child in the observation ward for the purpose of this study. This study was conducted in accordance with the Declaration of Helsinki and national and institutional standards. It was approved by the Ethics Committee of the Federal University of Bahia (approval reference number 24/2006) and registered with ClinicalTrials.gov (identifier NCT01200706).
Procedures
On recruitment, a thorough examination was performed; data on demographics, clinical history and physical examination were recorded in a standardized questionnaire. The pharmacy unit of the hospital was informed about the recruitment and independent pharmacists dispensed two bottles named Amoxicillin 1 and Amoxicillin 2 ( Figure S1 , available as Supplementary data at JAC Online): one bottle contained amoxicillin and the other placebo and vice versa, according to the randomization sequence.
The CXR was sent to two independent paediatric radiologists who were blinded to clinical information. Radiographic findings were registered on a pre-defined form in accordance with standardized interpretation. 9 Radiologically confirmed pneumonia was identified if there was agreement on the presence of pulmonary infiltrate/consolidation in two independent assessments.
Participants were followed up twice daily by trained medical students, who also observed the drug administration, supervised by a senior paediatrician from the research team. Data on complaints and findings were recorded on a standardized form. Each child was discharged from hospital when there was no more fever and respiratory discomfort and bottles of Amoxicillin 1 and Amoxicillin 2 were supplied to complete 10 days of treatment, according to the national guidelines. 10 On the fifth day of treatment, the senior paediatrician called the caregiver to enquire for symptoms and interventions. A final follow-up examination was performed 2 -4 weeks after enrolment, when a second CXR (frontal and lateral views) was taken. All data were registered on pre-defined forms. No change to the original protocol occurred after the trial commenced.
Definitions
Outcomes were defined a priori ( Table 2 ). The primary outcome was treatment failure up to 48 h. Secondary outcomes were cumulative treatment failure at up to 5 and 14 days. Anatomic abnormalities of the respiratory tract, cancer, chronic pulmonary illness besides asthma, immunological defects, progressing neurological disorders, psychomotor retardation, heart disease with clinical repercussion, haemoglobinopathy and liver or kidney disease. c Nutritional evaluation was performed using the software 'Anthro' (WHO); malnutrition and severe malnutrition were defined as Z-scores for weight-for-age under 22.00 and under 23.00, respectively. Fever: axillary temperature .37.58C.
11
c Tachypnoea: respiratory rate ≥50 breaths/min in children aged 2 -11 months and respiratory rate ≥40 breaths/min in children aged ≥12 months. 5 The upper record of axillary temperature and respiratory rate on each day was considered in the analysis.
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Sample size calculation
The sample size was estimated by the general formula for trials assessing equivalence. 12 The results of a previous study of 15 mg/kg oral amoxicillin every 8 h for the treatment of non-severe childhood pneumonia showed a 20% clinical failure rate. 13 Equivalence was defined a priori as ≤9% difference in the proportion of clinical failures between treatment groups at 2 days after enrolment. With a sample size of 410 participants in each arm, a two-group large sample approximation test of proportions with a one-sided 2.5% significance level has 90% power to reject the null hypothesis that there is a difference between the groups. The formal stopping rule prescribed that interim analysis should be performed if the intervention was discontinued in .30% of patients to investigate whether the new treatment was worse than the standard one.
Randomization and masking
Patients were randomly assigned to either amoxicillin thrice or twice daily, following a blocked design with a block size of four. The randomization sequence was created by a statistician who had no clinical involvement in the trial at the University of São Paulo School of Public Health using Stata 10 (StataCorp, 2007, College Station, TX, USA). Randomization codes were sealed in opaque envelopes in accordance with the allocation sequence and were provided to the pharmacist, who was aware of study group assignments at the time of dispensing the pair of bottles. Randomization code numbers were assigned to study participants in chronological order by the pharmacist. The sealed envelopes were kept stored in a strict area at the pharmacy unit during the collection and analysis of data. The next envelope in sequence was opened after enrolment and immediately before dispensing the drugs. The randomization sequence was only known by the researchers when the database was complete with the primary and secondary outcomes recorded for each patient. Participants and their respective families, healthcare providers, data collectors and outcome adjudicators were blinded to the intervention allocation. It was not necessary to unblind any participant or member of the research team during the trial.
Data entry and statistical analysis
Data were entered in the software EPI-INFO version 6.04 and analysed in Stata (version 11.0). The primary analysis was intention to treat and involved all patients who were randomly assigned. Participants excluded after randomization because they were found not to meet eligibility criteria (protocol violators), those who had the intervention stopped and those who were lost to follow-up ( Figure S2 , available as Supplementary data at JAC Online) were excluded from the secondary per-protocol analyses and were assumed to have treatment failure in the intention-to-treat analysis. We calculated the risk difference and two-sided 95% CI of the primary and secondary outcomes. The same approach was used in the subgroup of patients with concordant radiologically confirmed pneumonia. We also compared data between treatment success and failure groups at 48 h using Pearson's x 2 analysis for categorical variables and the Mann-Whitney U-test for continuous variables. Bivariate analysis included estimates of the OR and 95% CI. As a secondary goal, we constructed a multivariate model to look for determinants of treatment failure by forward stepwise logistic regression controlled by randomization, in all patients included in the per-protocol analysis. All significant variables from bivariate analysis were included in the model. Statistical significance was considered at the 5% level.
See Supplementary patients and methods (available as Supplementary data at JAC Online).
Results
From November 2006 to April 2011, 820 patients were enrolled and allocated into two groups: 412 were assigned to receive amoxicillin thrice daily and 408 twice daily, out of which 9 (2.2%) and 7 (1.7%) did not receive the allocated intervention, respectively ( Figure S2 ). The baseline characteristics of the two groups are shown in Table 3 .
The median (IQR) length of hospital stay was 2 (1 -2) days in both groups (P ¼ 0.6). At up to 48 h of treatment, the rate of treatment failure was judged equivalent across the two treatment arms in the intention-to-treat (23%) and the per-protocol (21%) analyses (Table 4) ; likewise, among the participants with concordant radiologically confirmed pneumonia (19%) ( Table 4) .
Cumulative treatment failure rates for up to 5 and 14 days of treatment are compared in Table 5 . Up to the 14 days follow-up visit, none died or presented inability to drink, grunting, nasal flaring or cyanosis. Concordant CXR reading was found in 97% of CXRs, out of which pneumonia (7%), normal CXR (89%) and other radiological diagnoses (4%) were diagnosed without difference in the compared groups (data not shown).
At the outpatient visit, adverse reactions were reported by 23 (6.1%) among 376 participants receiving amoxicillin thrice daily and by 28 (7.6%) among 369 receiving amoxicillin twice daily (P ¼ 0.5). Diarrhoea (n ¼ 20), urticaria (n ¼ 1), nausea (n ¼ 1) and abdominal pain (n ¼ 1) were reported in the former group and diarrhoea (n ¼ 27) and urticaria (n ¼ 1) in the latter group. Two adverse reactions were serious enough to discontinue intervention (one diarrhoea and one urticaria). Overall, adverse reaction rates reported at any time were 27 (6.8%) among 400 participants receiving amoxicillin thrice daily and 30 (7.5%) among 400 participants receiving amoxicillin twice daily (P ¼ 0.7). Serious adverse effects that led to interruption of the intervention occurred in five patients from the thrice daily doses group and in three patients from the twice daily doses group (1.3% versus 0.8%; P ¼ 0.7). The intervention was substituted in 20 (5%) patients in the thrice daily doses group and in 14 (3.5%) in the twice daily doses group (P ¼ 0.4) ( Table S1 , available as Supplementary data at JAC Online).
In logistic regression analysis of the baseline characteristics, wheezing, fever and tachypnoea were directly associated with failure and disease length ≥5 days and crackles were inversely associated with failure (Table 6) .
See Supplementary results (available as Supplementary data at JAC Online).
Discussion
We have demonstrated that amoxicillin given orally at 50 mg/kg/ day is equally efficacious thrice or twice daily at 48 h and beyond. The 48 h failure frequency was close to that reported (21%) when children with non-severe pneumonia received 15 mg/kg thrice daily. 13 Tachypnoea, fever and wheezing were independent predictors of failure and these findings are similar to what has been reported. 14 -16 Notably, the frequency of intervention substitution (5% and 3.5%) was much lower than the frequency of failure as it had been defined a priori in the protocol and no statistical significance was found by comparing trial arms.
Antibacterial therapy in pneumonia aims to eradicate the infecting organism. 17 Amoxicillin effect is time dependent and bacterial eradication is achieved when the unbound serum concentration exceeds the MIC of the causative pathogen for 40% -50% of the dosing interval. 18 Based on the current breakpoints established to determine pneumococcal susceptibility to Vilas-Boas et al.
antimicrobials 19 and data from invasive pneumococcal strains recovered from pneumonia cases between 2000 and 2005 in Latin America, the pneumococcal susceptibility to penicillin is 95.1%. 20 That is, this trial was conducted in a region with low prevalence of pneumococcal resistance to penicillin and this may explain why equivalence was found.
The identified predictors of failure (tachypnoea, fever and wheezing) are not novel. 14 -16 This finding suggests that they should alert paediatricians to follow up those patients with closer attention. Of note, the rate of intervention substitution (5% and 3.5%) was much lower than the failure rate defined a priori. Therefore, most of the patients who were classified as failure One patient who had the intervention interrupted at 48 h of use because of severe urticaria was included in this analysis because the intervention had been given for 48 h. One patient with concordant radiologically confirmed pneumonia was withdrawn from the trial. Amoxicillin given thrice or twice daily 1957 JAC continued to receive the intervention. This can be explained by the fact that the majority of cases judged to fail had persistence of signs present at enrolment. Indeed, only a few cases developed signs of severity or a severe adverse event (Table S1 ), when the intervention was substituted. The conservative definition for treatment failure was employed so that our data could be compared with previous studies. However, it has been shown that the alternative definition for therapy failure, which considers only cases who deteriorate, classifies a significantly lower number of cases as failure. 21 Moreover, such definition has worked reasonably well, without causing any higher risk to children with non-severe pneumonia. 21 Our findings support the use of these alternative criteria. Our findings on adverse reactions are in accordance with previous studies when ,10% of patients reported any such complaint, 22 severe events were rare, 13 discontinuation was not necessary in the great majority of patients and diarrhoea was the most frequent reaction. 13 In conclusion, amoxicillin may be given as a 25 mg/kg/dose twice a day to children with non-severe pneumonia because it is not only efficacious but also safe. Higher amounts of amoxicillin are unnecessary and money may be saved. Patients with fever, tachypnoea and wheezing should be followed up closely as they have a greater chance of failure. Randomization was not associated with failure in bivariate analysis but it was included in the logistic regression. One patient with concordant radiologically confirmed pneumonia was withdrawn from the trial and eight were lost to follow-up at 5 days.
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